Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites

Vaccine

Volumn 29, Issue 43, 2011, Pages 7335-7342

  Mishra, Satish ^a   Rai, Urvashi ^b   Shiratsuchi, Takayuki ^b   Li, Xiangming ^b   Vanloubbeeck, Yannick ^c   Cohen, Joe ^c   Nussenzweig, Ruth S ^a   Winzeler, Elizabeth A ^d,e   Tsuji, Moriya ^b   Nussenzweig, Victor ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Circumsporozoite protein (CSP); Malaria vaccine; Non CSP antigens; Plasmodium

Indexed keywords

ADENOVIRUS VECTOR; AG17 ANTIGEN; AG2 ANTIGEN; AG5 ANTIGEN; ASPARTIC PROTEINASE; CIRCUMSPOROZOITE PROTEIN; FALSTATIN; GAMMA INTERFERON; HEAT SHOCK PROTEIN; KRUPPEL LIKE FACTOR; NON CIRCUMSPOROZOITE PROTEIN; P36P ANTIGEN; PARASITE ANTIGEN; PFSUB 1 ANTIGEN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PROTEIN CLPB; SPOROZOITE SURFACE PROTEIN 2 PRECURSOR; TRAP LIKE PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG IDENTIFICATION; FEMALE; IMMUNOGENICITY; INTERFERON PRODUCTION; IRRADIATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE LOAD; PLASMODIUM YOELII; PRIORITY JOURNAL; SPLEEN CELL; SPOROZOITE; TRANSGENIC MOUSE; VIRUS RECOMBINANT; WILD TYPE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNIZATION; INTERFERON-GAMMA; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PLASMODIUM YOELII; PROTOZOAN PROTEINS; SPOROZOITES;

EID: 80053439053     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.081     Document Type: Article

References (49)

1. Kumar K.A., Sano G., Boscardin S., Nussenzweig R.S., Nussenzweig M.C., Zavala F., et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 2006, 444:937-940.
2. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216(5111):160-162.
3. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185:1155-1164.
4. Doolan D.L., Martinez-Alier N. Immune response to pre-erythrocytic stages of malaria parasites. Curr Mol Med 2006, 6(2):169-185.
5. Mueller A.K., Labaied M., Kappe S.H., Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005, 433:164-167.
6. Vaughan A.M., Wang R., Kappe S.H. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin 2010, 6:107-113.
7. Kumar K.A., Baxter P., Tarun A.S., Kappe S.H., Nussenzweig V. Conserved protective mechanisms in radiation and genetically attenuated uis3(-) and uis4(-) Plasmodium sporozoites. PLoS ONE 2009, 4:e4480.
8. Zavala F., Tam J.P., Hollingdale M.R., Cochrane A.H., Quakyi I., Nussenzweig R.S., et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 1985, 228(4706):1436-1440.
9. Romero P., Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., Zavala F., et al. Cloned cytotoxic T cells recognize an epitope on the circumsporozoite protein and protect against malaria. Nature 1989, 341:323-325.
10. + cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol 1991, 3:579-585.
11. + T cell clones against Plasmodium yoelii liver stages. J Immunol 1993, 150:1471-1478.
12. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 1998, 178:1139-1144.
13. Ballou W.R. Malaria vaccines in development. Expert Opin Emerg Drugs 2005, 10(3):489-493.
14. Cohen J., Nussenzweig V., Nussenzweig R., Vekemans J., Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin 2010, 6(1):90-96.
15. Sacarlal J., Aide P., Aponte J.J., Renom M., Leach A., Mandomando I., et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis 2009, 200:329-336.
16. Moorthy V.S., Imoukhuede E.B., Milligan P., Bojang K., Keating S., Kaye P., et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 2004, 1(2):e33.
17. Reyes-Sandoval A., Berthoud T., Alder N., Siani L., Gilbert S.C., Nicosia A., et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010, 78(1):145-153.
18. Kurtis J.D., Lanar D.E., Opollo M., Duffy P.E. Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum. Infect Immun 1999, 67(7):3424-3429.
19. Cummings J.F., Spring M.D., Schwenk R.J., Ockenhouse C.F., Kester K.E., Polhemus M.E., et al. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine 2010, 28(31):5135-5144.
20. Daubersies P., Ollomo B., Sauzet J.P., Brahimi K., Perlaza B.L., Eling W., et al. Genetic immunisation by liver stage antigen 3 protects chimpanzees against malaria despite low immune responses. PLoS ONE 2008, 3(7):e2659.
21. Bergmann-Leitner E.S., Legler P.M., Savranskaya T., Ockenhouse C.F., Angov E. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. Vaccine 2011, June.
22. Kariu T., Ishino T., Yano K., Chinzei Y., Yuda M. CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol Microbiol 2006, 59:1369-1379.
23. Bergmann-Leitner E.S., Mease R.M., De La Vega P., Savranskaya T., Polhemus M., Ockenhouse C., et al. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS ONE 2010, 5(8):e12294.
24. + T cell-mediated protective immunity against malaria. J Immunol 1997, 158:1268-1274.
25. Lasaro M.O., Ertl H.C. New insights on adenovirus as vaccine vectors. Mol Ther 2009, 17(8):1333-1339.
26. Reyes-Sandoval A., Wyllie D.H., Bauza K., Milicic A., Forbes E.K., Rollier C.S., et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 2011, June.
27. Le Roch K.G., Zhou Y., Blair P.L., Grainger M., Moch J.K., Haynes J.D., et al. Discovery of gene function by expression profiling of the malaria parasite lifecycle. Science 2003, 301(5639):1503-1508.
28. Zhou Y., Ramachandran V., Kumar K.A., Westenberger S., Refour P., Zhou B., et al. Evidence-based annotation of the malaria parasite's genome using comparative expression profiling. PLoS ONE 2008, 3(2):e1570.
29. Marti M., Good R.T., Rug M., Knuepfer E., Cowman A.F. Targeting malaria virulence and remodeling proteins to the host erythrocyte. Science 2004, 306:1930-1933.
30. Hiller N.L., Bhattacharjee S., van Ooij C., Liolios K., Harrison T., Lopez-Estrano C., et al. A host-targeting signal in virulence proteins reveals a secretome in malarial infection. Science 2004, 306:1934-1937.
31. Doolan D.L., Southwood S., Freilich D.A., Sidney J., Graber N.L., Shatney L., et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci USA 2003, 100:9952-9957.
32. + T cells using an ELISPOT assay. J Immunol Methods 1995, 181:45-54.
33. Labaied M., Harupa A., Dumpit R.F., Coppens I., Mikolajczak S.A., Kappe S.H. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun 2007, 75:3758-3768.
34. Douradinha B., van Dijk M.R., Ataide R., van Gemert G.J., Thompson J., Franetich J.F., et al. Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. Int J Parasitol 2007, 37(13):1511-1519.
35. Heiss K., Nie H., Kumar S., Daly T.M., Bergman L.W., Matuschewski K. Functional characterization of a redundant Plasmodium TRAP family invasin, TRAP-like protein, by aldolase binding and a genetic complementation test. Eukaryot Cell 2008, 7:1062-1070.
36. Moreira C.K., Templeton T.J., Lavazec C., Hayward R.E., Hobbs C.V., Kroeze H., et al. The Plasmodium TRAP/MIC2 family member, TRAP-Like Protein (TLP), is involved in tissue traversal by sporozoites. Cell Microbiol 2008, 10:1505-1516.
37. Bruña-Romero O., Hafalla J.C., González-Aseguinolaza G., Sano G., Tsuji M., Zavala F. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int J Parasitol 2001, 31(13):1499-1502.
38. Ophorst O.J., Radosević K., Havenga M.J., Pau M.G., Holterman L., Berkhout B., Goudsmit J., et al. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 2006, 74:313-320.
39. Kappe S.H., Buscaglia C.A., Nussenzweig V. Plasmodium sporozoite molecular cell biology. Annu Rev Cell Dev Biol 2004, 20:29-59.
40. Yoshida N., Potocnjak P., Nussenzweig V., Nussenzweig R.S. Biosynthesis of Pb44, the protective antigen of sporozoites of Plasmodium berghei. J Exp Med 1981, 154(4):1225-1236.
41. Gruner A.C., Mauduit M., Tewari R., Romero J.F., Depinay N., Kayibanda M., et al. Sterile protection against malaria is independent of immune responses to the circumsporozoite protein. PLoS ONE 2007, 2:e1371.
42. Schmidt N.W., Podyminogin R.L., Butler N.S., Badovinac V.P., Tucker B.J., Bahjat K.S., et al. Memory CD8T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci USA 2008, 105(37):14017-14022.
43. Schmidt N.W., Butler N.S., Badovinac V.P., Harty J.T. Extreme CD8T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog 2010, 6(7):e1000998.
44. Ferreira A., Schofield L., Enea V., Schellekens H., van der Meide P., Collins W.E., et al. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 1986, 232(4752):881-884.
45. Sharma S., Pahtak S. Malaria vaccine: a current perspective. J Vector Borne Dis 2008, 45:1-20.
46. Cockburn I.A., Chen Y.C., Overstreet M.G., Lees J.R., van Rooijen N., Farber D.L., et al. Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog 2010, 6(5):e1000877.
47. Singh A.P., Buscaglia C.A., Wang Q., Levay A., Nussenzweig D.R., Walker J.R., et al. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 2007, 131(3):492-504.
48. Hoffman S.L., Doolan D.L. Malaria vaccines-targeting infected hepatocytes. Nat Med 2000, 6(11):1218-1219.
49. Limbach K., Aguiar J., Gowda K., Patterson N., Abot E., Sedegah M., et al. Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates. Malaria J 2011, 10:65.